Oral, once-daily, single-agent therapy fills an unmet need for new treatment options to help Canadians in the fight against this deadly disease TORONTO, July 30, 2015 /CNW/ - Janssen Inc. announced today that Health Canada has issued a Notice of ... Canada NewsWire, 1 month ago
IMBRUVICA (ibrutinib) Approved with Conditions for Relapsed or Refractory Mantle Cell Lymphoma Patients - Pharmacy Choice, 1 month ago
AbbVie has received marketing approval from the European Commission (EC) for its Imbruvica (ibrutinib) to treat patients with Waldenstrom's macroglobulinemia (WM), a rare and slow-growing blood cancer. Approval was granted for the drug to treat WM ...Pharmaceutical Technology, 1 month ago AbbVie receives European approval for Humira to treat hidradenitis suppurativa CPhI.cn, 1 month ago
Janssens IMBRUVICA®▼(Ibrutinib) erhält zusätzliche Zulassung der EU-Kommission für die Behandlung von Waldenströms Makroglobulinämie
Janssen's IMBRUVICA ® ▼(ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström's Macroglobulinemia Ibrutinib now the first EC-approved treatment option available for this rare B-cell lymphoma ...PR Newswire, 1 month ago
Chicago—The addition of ibrutinib reduces the risk for death or disease progression over that provided by bendamustine and rituximab (BR) alone in previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), ...Pharmacy Practice News, 1 month ago European Imbruvica approval for Janssen Pharmafile, 1 month ago IMBRUVICA (ibrutinib) receives additional European Commission approval for the treatment of Waldenström's Macroglobulinemia Medical News Today, 1 month ago Ibrutinib recieves additional European Commission approval for the treatment of Waldenström's Macroglobulinemia Ecancer Medicalscience, 1 month ago
Today AbbVie (NYSE: ABBV) announced the European Commission (EC) granted marketing authorization for IMBRUVICA ® (ibrutinib) as the first treatment option available in all 28 member states of the European Union (EU) for the treatment of ...News-Medical.Net, 1 month ago Imbruvica cleared in Europe for Waldenstrom's macroglobulinemia Seeking Alpha, 1 month ago Europe clears AbbVie's Imbruvica for Waldenstrom's macroglobulinaemia FirstWord Pharma, 1 month ago IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe Crawford Financial Planning, 1 month ago
CORRECTION - Janssen-Cilag International NV: Janssen's IMBRUVICA®▼ (ibrutinib) Receives Additional European..
/PRNewswire/ -- We would like to advise journalists and other readers that the news release "Janssen's IMBRUVICA®▼ (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström's Macroglobulinemia" issued on 10 ...ADVFN India, 1 month ago
More from: , ADVFN UK...and 2 other sources
TG-1101 also appeared to abrogate ibrutinib related lymphocytosis with patients experiencing a median 75% reduction in their absolute lymphocyte count (ALC) by the end of month 3 following initiation of combination therapy and 70% of patients ...Individual.com, 2 months ago TG Therapeutics, Inc. Announces Second Quarter 2015 Financial Results And Business Update TheStreet.com, 3 weeks ago
IMBRUVICA®▼(ibrutinib) de Janssen reçoit une autre approbation donnée par la Commission européenne pour le traitement de la macroglobulinémie…Gnom.es, 1 month ago
(RTTNews.com) - AbbVie ( ABBV ) announced the European Commission has granted marketing authorization for IMBRUVICA (ibrutinib) for the treatment of Waldenstrom's macroglobulinemia, a rare, slow growing blood cancer, in adult patients who have ...Nasdaq, 1 month ago EU grants marketing approval for Imbruvica to treat Waldenstrom's macroglobulinemia PharmaBiz, 1 month ago
Patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease, a newScience Daily, 1 month ago The Leukemia & Lymphoma Society Applauds Encouraging Data From a Phase 2 Study of Venetoclax for a High-Risk Subset of Chronic Lymphocytic Leukemia Patients Sys-Con Media, 2 weeks ago Researchers Use Precision Medicine in Common Type of Lymphoma American Journal of Managed Care, 1 month ago Drug shows promise for patients with chronic lymphocytic leukemia City of Hope, 2 months ago
More from: , PressReleasePoint...and 5 other sources
on your WebpageAdd Widget >Get your members hooked!